Narrative review based on fingolimod therapy in pediatric MS

Area of Science:

• Neurology
• Pediatrics
• Immunology

Background:

• Pediatric-onset multiple sclerosis (MS) presents distinct clinical patterns compared to adult-onset MS.
• Children with MS often experience a more aggressive initial disease course but demonstrate a higher rate of complete recovery after the first event.

Purpose of the Study:

• To review existing literature on the safety and efficacy of disease-modifying treatments (DMTs) in pediatric-onset MS.
• To highlight the unique aspects of pediatric MS management, including treatment considerations and clinical trial limitations.

Main Methods:

• Literature review of published data on pediatric-onset multiple sclerosis.
• Analysis of clinical differences, recovery rates, and disability progression between pediatric and adult MS patients.
• Evaluation of treatment options, including injectable, oral, and infusion therapies, with a focus on fingolimod.

Main Results:

• The rate of a second attack is higher in children (80%) versus adults (45%), with similar timing.
• Pediatric MS patients show slower long-term disability accumulation despite aggressive onset, attributed to brain plasticity.
• Fingolimod demonstrates a relatively favorable safety and efficacy profile in pediatric MS, based on available data.

Conclusions:

• Pediatric-onset MS requires tailored management strategies considering its unique disease course and treatment response.
• Limited clinical trial data in pediatric MS necessitates careful consideration of DMTs, such as fingolimod.
• Further research is crucial to fully elucidate the long-term outcomes and optimal treatment paradigms for pediatric MS.